Milford Pharma Firm Launches Drug Trial
Spring Bank Pharmaceuticals of Milford said it has begun dosing in a Phase I clinical study of its drug for patients with Hepatitis C.
The study will be conducted in healthy, infected patients and is designed to assess both the safety and antiviral effectiveness of the hepatitis drug, called SB 9200. Spring Bank's CEO, Doug Jensen, said the start of the clinical trial the drug "is an important milestone for our company."
"This trial should not only give us proof of concept in (Hepatitis C, also known as HCV), but also will facilitate the advancement of our technology in other viral diseases," such as Hepatitis B (HBV) and respiratory syncytial virus, or RSV, Jensen added.
The clinical trial is being conducted in Australia with plans to expand it into New Zealand, the company said.
WBJ Web Partners
Most Recent
Most Recent
0 Comments